Inventor · disambiguated record
Zhuoxiao Cao
Also filed as: CAO ZHUOXIAO
6 granted patents·32 pending applications·1 citations·filing 2017–2025
69Inventor score
Files withJIANGSU HENGRUI MEDICINE CO9SHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD8SIMCERE ZAIMING PHARMACEUTICAL CO LTD6HAINAN SIMCERE PHARMACEUTICAL CO LTD3HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO LTD3
Top patents by PatentIndex Score
38 records- 0177US12319725B2IL-2 mutant and application thereofHAINAN SIMCERE PHARMACEUTICAL CO LTD·Filed 2024·Granted Jun 3, 2025·0 cites·16 claims
- 0275US2025382343A1Il-2 Mutants And Uses ThereofHAINAN SIMCERE PHARMACEUTICAL CO LTD·Filed 2025·Application pending·0 cites
- 0373US11345753B2TIM-3 antibody, antigen binding fragment thereof, and medicinal uses thereofJIANGSU HENGRUI MEDICINE CO·Filed 2018·Granted May 31, 2022·1 cites·18 claims
- 0472US2024209051A1Il-2 Mutant And Application ThereofHAINAN SIMCERE PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 0569US11981733B2LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereofJIANGSU HENGRUI MEDICINE CO·Filed 2021·Granted May 14, 2024·0 cites·20 claims
- 0665US12421286B2Il-2 mutant and application thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2021·Granted Sep 23, 2025·0 cites·14 claims
- 0762US11155617B2LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereofJIANGSU HENGRUI MEDICINE CO·Filed 2017·Granted Oct 26, 2021·0 cites·21 claims
- 0859US2025353907A1Cd19-targeting chimeric antigen receptor and use thereofSHANGHAI SIMNOVA BIOTECHNOLOGY CO LTD·Filed 2023·Application pending·0 cites
- 0959US2025304717A1Camptothecin derivative and ligand-drug conjugateHAINAN SIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1056US2025213694A1Enhanced chimeric antigen receptor and use thereofSHANGHAI SIMNOVA BIOTECHNOLOGY CO LTD·Filed 2023·Application pending·0 cites
- 1154US2022153853A1Bispecific proteinJIANGSU HENGRUI MEDICINE CO·Filed 2019·Application pending·0 cites
- 1253US11512129B2TIGIT antibody, antigen-binding fragment thereof, and medical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2018·Granted Nov 29, 2022·0 cites·19 claims
- 1353US2025009847A1Il-15 mutant fusion protein pharmaceutical compositionSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1451US2024343803A1Anti-Pvrig/Anti-Tigit Bispecific Antibodies And Applications ThereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1551US2024124575A1Human cd33 antibody and use thereofSIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1650US2025075006A1Anti-gucy2c nano-antibody and application thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1750US2024307415A1Steroid compound, and pharmaceutical composition thereof and use thereofJIANGSU SIMCERE PHARM CO LTD·Filed 2022·Application pending·0 cites
- 1850US2025297021A1Bcma antibody and use thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO NO 1·Filed 2022·Application pending·0 cites
- 1949US2024343811A1Cd16 antibody and use thereofSHANDONG SIMCERE BIOPHARMACUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2049US2025297030A1Anti-muc17 nanobody and use thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2149US2025042994A1Cd19 antibody and application thereofHAINAN SIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2249US2025145705A1Gprc5d antibody and application thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2348US2022220218A1Anti-cd73 antibody, antigen-binding fragment thereof and application thereofJIANGSU HENGRUI MEDICINE CO·Filed 2019·Application pending·0 cites
- 2448US2021261663A1Anti-tim3 antibody pharmaceutical composition and use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2019·Application pending·0 cites
- 2548US2025136687A1Anti-human cd3 antibody and use thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2647US2024084003A1Anti-human cd22 monoclonal antibodies and use thereofSIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2747US2025179172A1Cd5 antibody and use thereofHAINAN SIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 2847US2024109974A1Humanized antibody against tnfr2 and use thereofJIANGSU SIMCERE PHARM CO LTD·Filed 2022·Application pending·0 cites
- 2946US2023416360A1Anti-cd22 nano antibody and use thereofSIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3046US2025250357A1Anti-msln antibody and application thereofNANJING ZAIMING PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 3146US2025026844A1Anti-bcma nanobody and use thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 3245US2020347130A1CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use ThereofJIANGSU HENGRUI MEDICINE CO·Filed 2018·Application pending·0 cites
- 3345US2022017618A1Use of tim-3 antibody in preparation of medicines for treating tumorsJIANGSU HENGRUI MEDICINE CO·Filed 2019·Application pending·0 cites
- 3444US2023192797A1Human il-15 mutant and uses thereofJIANGSU SIMCERE PHARM CO LTD·Filed 2021·Application pending·0 cites
- 3543US2024076403A1Her2 antibody and application thereofSIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3641US2024124563A1Anti-Human MSLN Antibody And Application ThereofNANJING ZAIMING PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3740US2024052055A1Gpc3 antibody and application thereofSIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3840US2024101686A1Anti-egfr nanobody and use thereofSIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →